Cargando…

Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction

Busulfan (Bu) is an alkylating agent commonly used at high doses in the preparative regimens of hematopoietic stem cell transplantation (HSCT). It has been shown that such high doses of Bu are associated with generalized seizures which are usually managed by prophylactic antiepileptic drugs (AEDs) s...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Enezi, Bashayer F., Al-Hasawi, Nada, Matar, Kamal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876357/
https://www.ncbi.nlm.nih.gov/pubmed/36696427
http://dx.doi.org/10.1371/journal.pone.0280574
_version_ 1784878148135944192
author Al-Enezi, Bashayer F.
Al-Hasawi, Nada
Matar, Kamal M.
author_facet Al-Enezi, Bashayer F.
Al-Hasawi, Nada
Matar, Kamal M.
author_sort Al-Enezi, Bashayer F.
collection PubMed
description Busulfan (Bu) is an alkylating agent commonly used at high doses in the preparative regimens of hematopoietic stem cell transplantation (HSCT). It has been shown that such high doses of Bu are associated with generalized seizures which are usually managed by prophylactic antiepileptic drugs (AEDs) such as valproic acid (VPA). Being a strong enzyme inhibitor, VPA may inhibit Bu metabolism and thus increase its potential toxicity. Despite its clinical relevance, the potential interaction between Bu and VPA has not yet been evaluated. The aim of the present study was to assess and evaluate the potential drug-drug interaction (DDI) between Bu and VPA. This study was carried out by incubating Bu in laboratory-prepared rat liver-subcellular fractions including S9, microsomes, and cytosol, alone or in combination with VPA. The liver fractions were prepared by differential centrifugation of the liver homogenate. Analysis of Bu was employed using a fully validated LC-MS/MS method. The validation parameters were within the proposed limits of the international standards guidelines. Bu metabolic stability was assessed by incubating Bu at a concentration of 8 μg/ml in liver fractions at 37°C. There were significant reductions in Bu levels in S9 and cytosolic fractions, whereas these levels were not significantly (P ˃ 0.05) changed in microsomes. However, in presence of VPA, Bu levels in S9 fraction remained unchanged. These results indicated, for the first time, the potential metabolic interaction of Bu and VPA being in S9 only. This could be explained by inhibiting Bu cytosolic metabolism by the interaction with VPA either by sharing the same metabolic enzyme or the required co-factor. In conclusion, the present findings suggest, for the first time, a potential DDI between Bu and VPA in vitro using rat liver fractions. Further investigations are warranted in human-derived liver fractions to confirm such an interaction.
format Online
Article
Text
id pubmed-9876357
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98763572023-01-26 Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction Al-Enezi, Bashayer F. Al-Hasawi, Nada Matar, Kamal M. PLoS One Research Article Busulfan (Bu) is an alkylating agent commonly used at high doses in the preparative regimens of hematopoietic stem cell transplantation (HSCT). It has been shown that such high doses of Bu are associated with generalized seizures which are usually managed by prophylactic antiepileptic drugs (AEDs) such as valproic acid (VPA). Being a strong enzyme inhibitor, VPA may inhibit Bu metabolism and thus increase its potential toxicity. Despite its clinical relevance, the potential interaction between Bu and VPA has not yet been evaluated. The aim of the present study was to assess and evaluate the potential drug-drug interaction (DDI) between Bu and VPA. This study was carried out by incubating Bu in laboratory-prepared rat liver-subcellular fractions including S9, microsomes, and cytosol, alone or in combination with VPA. The liver fractions were prepared by differential centrifugation of the liver homogenate. Analysis of Bu was employed using a fully validated LC-MS/MS method. The validation parameters were within the proposed limits of the international standards guidelines. Bu metabolic stability was assessed by incubating Bu at a concentration of 8 μg/ml in liver fractions at 37°C. There were significant reductions in Bu levels in S9 and cytosolic fractions, whereas these levels were not significantly (P ˃ 0.05) changed in microsomes. However, in presence of VPA, Bu levels in S9 fraction remained unchanged. These results indicated, for the first time, the potential metabolic interaction of Bu and VPA being in S9 only. This could be explained by inhibiting Bu cytosolic metabolism by the interaction with VPA either by sharing the same metabolic enzyme or the required co-factor. In conclusion, the present findings suggest, for the first time, a potential DDI between Bu and VPA in vitro using rat liver fractions. Further investigations are warranted in human-derived liver fractions to confirm such an interaction. Public Library of Science 2023-01-25 /pmc/articles/PMC9876357/ /pubmed/36696427 http://dx.doi.org/10.1371/journal.pone.0280574 Text en © 2023 Al-Enezi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Al-Enezi, Bashayer F.
Al-Hasawi, Nada
Matar, Kamal M.
Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title_full Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title_fullStr Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title_full_unstemmed Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title_short Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
title_sort impact of valproic acid on busulfan pharmacokinetics: in vitro assessment of potential drug-drug interaction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876357/
https://www.ncbi.nlm.nih.gov/pubmed/36696427
http://dx.doi.org/10.1371/journal.pone.0280574
work_keys_str_mv AT alenezibashayerf impactofvalproicacidonbusulfanpharmacokineticsinvitroassessmentofpotentialdrugdruginteraction
AT alhasawinada impactofvalproicacidonbusulfanpharmacokineticsinvitroassessmentofpotentialdrugdruginteraction
AT matarkamalm impactofvalproicacidonbusulfanpharmacokineticsinvitroassessmentofpotentialdrugdruginteraction